Skip to main content
Terug
LFTSF logo

LifeTech Scientific Corporation

Datakwaliteit: 100%
Overbought
LFTSF
OTC Healthcare Medical - Devices
€ 0,23
€ 0,00 (0,00%)
Marktkapitalisatie: 1,03B
Dagbereik
€ 0,23 € 0,23
52-Weeksbereik
€ 0,23 € 0,23
Volume
100
50D / 200D Gem.
€ 0,23 / € 0,23
Vorige Slotkoers
€ 0,23

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 4,6 0,3
P/B 0,3 2,9
ROE % 6,5 3,7
Net Margin % 17,1 3,8
Rev Growth 5Y % 19,4 10,0
D/E 0,0 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 € 0,11
€ 0,11 – € 0,11
 1,7 B 1
FY2026 € 0,08
€ 0,08 – € 0,08
 1,5 B 1

Belangrijkste Punten

Revenue grew 19,36% annually over 5 years — strong growth
Earnings declined -15,52% over the past year
Net margin of 17,06% shows strong profitability
Debt/Equity of 0,00 — conservative balance sheet
Generating 38,46M in free cash flow
P/E of 4,62 — trading at a low valuation

Groei

Revenue Growth (5Y)
19,36%
Revenue (1Y)2,88%
Earnings (1Y)-15,52%
FCF Growth (3Y)-14,69%

Kwaliteit

Return on Equity
6,48%
ROIC3,99%
Net Margin17,06%
Op. Margin14,29%

Veiligheid

Debt / Equity
0,00
Current Ratio2,86
Interest Coverage98,59

Waardering

P/E Ratio
4,62
P/B Ratio0,29
EV/EBITDA1,97
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 2,88% Revenue Growth (3Y) 9,00%
Earnings Growth (1Y) -15,52% Earnings Growth (3Y) -17,32%
Revenue Growth (5Y) 19,36% Earnings Growth (5Y) 0,72%
Profitability
Revenue (TTM) 1,30B Net Income (TTM) 222,39M
ROE 6,48% ROA 4,54%
Gross Margin 75,28% Operating Margin 14,29%
Net Margin 17,06% Free Cash Flow (TTM) 38,46M
ROIC 3,99% FCF Growth (3Y) -14,69%
Safety
Debt / Equity 0,00 Current Ratio 2,86
Interest Coverage 98,59 Dividend Yield 0,00%
Valuation
P/E Ratio 4,62 P/B Ratio 0,29
P/S Ratio 0,79 PEG Ratio -2,48
EV/EBITDA 1,97 Dividend Yield 0,00%
Market Cap 1,03B Enterprise Value 366,80M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 1,30B 1,27B 1,10B 925,33M 642,30M
Net Income 222,39M 263,24M 325,34M 292,47M 216,09M
EPS (Diluted) 0,05 0,06 0,07 0,06 0,05
Gross Profit 981,44M 995,64M 873,93M 747,53M 513,15M
Operating Income 186,34M 383,28M 375,93M 328,74M 264,49M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 4,90B 4,70B 3,69B 3,18B 2,95B
Total Liabilities 1,42B 1,37B 769,05M 653,61M 596,06M
Shareholders' Equity 3,49B 3,37B 2,90B 2,50B 2,34B
Total Debt 4,98M 9,30M 9,67M 15,67M 185,98M
Cash & Equivalents 665,76M 979,31M 833,79M 1,12B 971,68M
Current Assets 2,33B 2,23B 1,40B 1,84B 1,54B
Current Liabilities 815,64M 770,14M 584,74M 481,91M 493,60M

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#730 of 827
20
Value Defensive Investing (Benjamin Graham)
#135 of 709
50

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026